United States · Addiction Treatment startup
United States · Euthymics Bioscience
Euthymics Bioscience, a neuroscience-focused biopharmaceutical company, develops medicines for central nervous system disorders.
Funding reportedLast round: Series A
What company datasets say Euthymics Bioscience raised
Funding, as reported
Reported in all$39Min dollars
Rounds3
Last roundSeries A
Last round dateApr 2014
Investors listed6
Founders and team
From the SEC filings it signed: 3 on the team.
- Anthony McKinneyPresident and Chief Executive Officeri
- William PappafotopoulosChief Accounting and Administrative Officeri
- Albert L. SokolSecretaryi
On the board, as filediBrigitte SmithCampbell MurrayDaniel OmsteadJeffrey BaileyPaul WeissTimothy Barberich
On a portfolio page
Investors who name them
Each firm lists Euthymics Bioscience on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.
Addiction Treatment in United States
Startups like it
Is this your company?
Add your raise, your deck and your story, and put Euthymics Bioscience in front of investors. Or tell us what we have wrong.